As previously reported [4, 14, 25–27], we found that a substantial proportion of MM had alterations in the genes involved in the MAPK pathway, including frequent mutations in BRAF, KIT, RAS, and NF1. It is well known that a BRAF mutation provides a targeted therapy for melanoma with good efficacy [28]. This evidence concerns the gene KIT and melanoma.